CD19 and COVID-19: It was reported that CLL patients with diminished numbers of functional CD19+ B-cells, a key player in the humoral response against the SARS-CoV-2 virus, developed T-cell immune responses to COVID-19 vaccination, which were, however, dependent on the current treatment status [12].